Morgan Stanley analyst Jeffrey Hung initiates coverage on $BioAge Labs (BIOA.US)$ with a buy rating, and sets the target price at $40.
According to TipRanks data, the analyst has a success rate of 59.7% and a total average return of 19.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $BioAge Labs (BIOA.US)$'s main analysts recently are as follows:
BioAge Labs is a clinical-stage biotechnology firm concentrated on the progression of therapies targeting metabolic diseases. The company's primary candidate, azelaprag, is an orally administered, small molecule that stimulates the apelin receptor and is currently being developed to address obesity. There is an anticipation of a favorable risk/reward situation for the company's shares leading up to the STRIDES outcome, bolstered by azelaprag's oral administration, straightforward manufacturing, and substantial preclinical evidence that suggests a promising clinical profile in the treatment of obesity.
Initial findings suggest that BioAge Labs' azelaprag may facilitate weight loss when used alongside GLP-1s, and could also enhance body composition and the quality of weight loss. Early evidence points toward azelaprag's ability to promote weight reduction while simultaneously providing muscle benefits.
BioAge Labs is recognized as a clinical-stage biotech company with a focus on metabolic diseases. The lead drug, Azelaprag, is noted for its unique approach as an exercise mimetic in the treatment of obesity.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
摩根士丹利分析師Jeffrey Hung首次給予$BioAge Labs (BIOA.US)$買入評級，目標價40美元。
根據TipRanks數據顯示，該分析師近一年總勝率為59.7%，總平均回報率為19.7%。
此外，綜合報道，$BioAge Labs (BIOA.US)$近期主要分析師觀點如下：
BioAge Labs是一家臨床階段的生物技術公司，專注於針對代謝疾病的療法的進展。該公司的主要候選藥物azelaprag是一種口服給藥的小分子，可刺激apelin受體，目前正在開發用於解決肥胖問題。在azelaprag的口服給藥、直截了當的製造以及表明肥胖症治療臨床前景光明的大量臨床前證據的支持下，預計該公司的股票將出現有利的風險/回報狀況，從而推動STRIDES的業績。
初步發現表明，BioAge Labs的azelaprag與GLP-1一起使用可以促進減肥，還可以增強身體成分和減肥質量。早期的證據表明，azelaprag能夠促進減肥，同時提供肌肉益處。
BioAge Labs被公認爲一家專注於代謝疾病的臨床階段生物技術公司。主要藥物Azelaprag因其作爲治療肥胖症的運動模擬劑的獨特方法而聞名。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
